Therapeutic Utility of Xolair in Patients Undergoing Aspirin Desensitization

This study is currently recruiting participants. (see Contacts and Locations)
Verified March 2015 by The Cleveland Clinic
Genentech, Inc.
Information provided by (Responsible Party):
David Lang, Cleveland Clinic Foundation Identifier:
First received: November 7, 2007
Last updated: March 12, 2015
Last verified: March 2015

This is a 24 week double-blind study consisting of up to 11 office visits for people 18 years of age with aspirin exacerbated respiratory disease (AERD). 21 subjects will participate and will be randomized 2:1 to receive Xolair (Omalizumab) or placebo. 14 subjects will receive Xolair and 7 will receive placebo. Xolair is a FDA approved medication for the treatment of moderate to severe allergic asthma. Injections will occur every 2-4 weeks, for 16 weeks. The dosage will be based upon IgE and body weight. Aspirin desensitization will occur 1-3 weeks later. One month after desensitization, the final visit will occur in the GCRC.

Properly selected patients with aspirin exacerbated respiratory disease (AERD) experience benefit in the course of their disease with aspirin desensitization treatment; however, AERD patients are at risk for potentially serious asthmatic reaction when undergoing aspirin desensitization. For this reason, this procedure is currently performed in a monitored setting. We hypothesize that administration of Xolair, a monoclonal anti-IgE antibody, prior to the aspirin desensitization will reduce severity of aspirin-induced respiratory reaction, and that ultimately, use of Xolair will permit this procedure to be performed safely in outpatient settings. This protocol also entails obtaining blood and urine samples to assess the influence of Xolair, compared with placebo. As aspirin induced reaction occurs via heightened release of leukotrienes combined with greater end organ responsiveness to these mediators, we also will be quantifying the impact of prior administration of Xolair, compared with placebo, on the elevation of urinary LTE4 in association with aspirin challenge and with aspirin provoked reaction.

Condition Intervention Phase
Aspirin Exacerbated Respiratory Disease
Drug: omalizumab
Phase 4

Study Type: Interventional
Study Design: Allocation: Randomized
Endpoint Classification: Safety/Efficacy Study
Intervention Model: Single Group Assignment
Masking: Double Blind (Subject, Caregiver, Investigator)
Primary Purpose: Prevention
Official Title: A Placebo Controlled, Double-Blind Investigation of the Therapeutic Utility of Xolair (Omalizumab) for Attenuating Aspirin Induced Bronchospasm in Patients With Aspirin Exacerbated Respiratory Disease (AERD) Undergoing Aspirin Desentization

Resource links provided by NLM:

Further study details as provided by The Cleveland Clinic:

Primary Outcome Measures:
  • Spirometry (FEV1) testing to assess the efficacy of Xolair on aspirin induced bronchospasm during aspirin desensitization in patients with AERD. [ Time Frame: 24 weeks ] [ Designated as safety issue: Yes ]

Secondary Outcome Measures:
  • Changes in serum and urinary markers of eosinophil activation during desensitization and change in urinary LTE4 during bronchospasm. Assessment of aspirin dose that provokes reaction. [ Time Frame: Approximately 24 weeks ] [ Designated as safety issue: Yes ]

Estimated Enrollment: 21
Study Start Date: May 2006
Estimated Study Completion Date: September 2015
Estimated Primary Completion Date: September 2015 (Final data collection date for primary outcome measure)
Arms Assigned Interventions
Placebo Comparator: 1
Study drug versus placebo
Drug: omalizumab
Dosage (150 - 375 mg) based on IgE levels; administered subcutaneously every 2-4 weeks for 16 weeks.
Other Name: Xolair


Ages Eligible for Study:   18 Years and older
Genders Eligible for Study:   Both
Accepts Healthy Volunteers:   No

Inclusion Criteria:

  • Age > 18 years.
  • Fulfill diagnostic criteria for AERD (described below), and be a candidate for aspirin desensitization chronic asthma - frequently moderate-severe or severe patients will have history compatible with variable airflow obstruction. patients will have exhibited ≥ 12% increase in FEV1 following bronchodilator. chronic rhinosinusitis - usually requiring previous sinus surgery procedure(s). sinusitis will have been confirmed by imaging studies presently and/or in the past.

history of adverse reaction to aspirin and/or aspirin-like drugs (e.g., ibuprofen, naproxen, etc.) compatible with AERD.

• Candidate for Xolair [Omalizumab] Moderate-severe persistent asthma IgE = 30-700 IU/ml IgE mediated (allergic) potential to inhalant allergen(s) by cutaneous or in vitro testing.

Exclusion Criteria:

  • Women of childbearing potential not using appropriate contraception method(s)
  • Women currently breastfeeding
  • Women who desire to become pregnant during the time of participation in this study
  • Men who desire to get someone pregnant during participation in this study
  • Known sensitivity to Xolair [Omalizumab].
  • IgE level < 30 IU/ml, or > 700 IU/ml.
  • No evidence of atopy by immediate hypersensitivity skin testing
  • Use of any other investigational agent in the last 30 days
  • Age < 18 years.
  • Current tobacco habituation.
  • Presence of emphysema
  • Ethanolism or drug abuse within last 12 months.
  • Presence of significant medical condition including malignancy, neurologic, kidney, gastrointestinal, liver or cardiovascular disease
  • extensive travel commitments during the study that would interfere with study measurements or clinic visits.
  Contacts and Locations
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below. For general information, see Learn About Clinical Studies.

Please refer to this study by its identifier: NCT00555971

Contact: Bette Maierson, BA RRT 216/444-2901

United States, Ohio
The Cleveland Clinic Recruiting
Cleveland, Ohio, United States, 44195
Contact: Bette Maierson, BA RRT    216-444-2901   
Principal Investigator: David M Lang, M.D.         
Sponsors and Collaborators
David Lang
Genentech, Inc.
Principal Investigator: David M. Lang, M.D. The Cleveland Clinic, Department of Allergy and Immunology
  More Information

No publications provided

Responsible Party: David Lang, Chairman, Allergy and Immunology, Cleveland Clinic Foundation Identifier: NCT00555971     History of Changes
Other Study ID Numbers: IRB 05-066  Q3637s 
Study First Received: November 7, 2007
Last Updated: March 12, 2015
Health Authority: United States: Food and Drug Administration

Additional relevant MeSH terms:
Respiration Disorders
Respiratory Tract Diseases
Anti-Allergic Agents
Anti-Asthmatic Agents
Pharmacologic Actions
Respiratory System Agents
Therapeutic Uses processed this record on February 04, 2016